Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MGD013 in Advanced Melanoma
NCT04653038Phase 1Terminated
- Sponsor
- Zai Lab
- Start
- Oct 2020
- Primary completion
- Mar 2022
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of tebotelimab in Malignant Melanoma (MM) (2 arms), sponsored by Zai Lab. Primary endpoint: Objective Response Rate at 12 months. Started Oct 2020; status: terminated.
02
Drugs
tebotelimab
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT04653038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04653038.